EcoDrugPlus

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSAMXG00000034348
Gene Symbol: LOC103038676
3 Cross references
190 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSAMXG00000043241
Gene Symbol: CXCR1
3 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSAMXG00000037729
Gene Symbol: CXCR4
3 Cross references
205 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSAMXG00000000420
Gene Symbol: CFTR
3 Cross references
217 Possible Orthologues:

D(2) Dopamine Receptor A

Ensembl ID : ENSAMXG00000007381
Gene Symbol: LOC103035621
3 Cross references
145 Possible Orthologues:

D(2)-Like Dopamine Receptor

Ensembl ID : ENSAMXG00000018359
Gene Symbol: LOC103036974
3 Cross references
204 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSAMXG00000012182
Gene Symbol: DNMT1
1 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSAMXG00000020451
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSAMXG00000012125
Gene Symbol: TOP2A
1 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSAMXG00000010783
Gene Symbol: TOP2B
1 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSAMXG00000005023
Gene Symbol: EML4
2 Cross references
212 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSAMXG00000016897
Gene Symbol: EPHA3
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).